Search CTL/CD8+ T-Cell Epitope Database

Found 2 matching records:

Displaying record number 1066

Download this epitope record as JSON.

HXB2 Location	Nef(134-144) DNA(9196..9228)	Nef Epitope Map
Author Location	Nef(134-144 LAI)
Epitope	RYPLTFGWCYK	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(B18)
Immunogen	HIV-1 infection
Experimental methods
Keywords	review, escape

Notes

• Mutational variation in HIV epitopes in individuals with appropriate HLA types can result in evasion of CTL response.
• Mutants with T5C mutation (RYPLcFGWCYK) evade HLA-B18-restricted CTL responses.
• Goulder1997e is a review of immune escape that summarizes this study.

References

Couillin1994 I. Couillin, B. Culmann-Penciolelli, E. Gomard, J. Choppin, J. P Levy, J. G. Guillet, and S. Sarasgosti. Impaired Cytotoxic T Lymphocyte Recognition Due to Genetic Variations in the Main Immunogenic Region of the Human Immunodeficiency Virus 1 NEF Protein. J. Exp. Med., 180:1129-11234, 1994. HIV-1 HLA-A11 and -B18 restricted epitopes were sequenced from donors who do and do not express the HLA-A11 and B18 molecule. Selective variations were only detected in virus isolated from individuals expressing the appropriate HLA type. Variant peptides with single substitutions within the minimal epitope did not always completely abrogate HLA binding, suggesting that multiple alterations within a particular epitope may need to accumulate during disease progression to allow viral escape. PubMed ID: 7520468. Show all entries for this paper.

Goulder1997e P. Goulder, D. Price, M. Nowak, S. Rowland-Jones, R. Phillips, and A. McMichael. Co-Evolution of Human Immunodeficiency Virus and Cytotoxic T-Lymphocyte Responses. Immunol. Rev., 159:17-29, 1997. PubMed ID: 9416500. Show all entries for this paper.

Displaying record number 1383

Download this epitope record as JSON.

HXB2 Location	Nef(134-144) DNA(9196..9228)	Nef Epitope Map
Author Location	Nef(134-144)
Epitope	RYPLTFGWCYK	Epitope Alignment
Epitope Name	RYP
Species (MHC/HLA)	human(B18)
Immunogen	HIV-1 infection
Experimental methods
Keywords	HAART, ART, acute/early infection

Notes

• Patients who started therapy at acute HIV-1 infection (three with sustained therapy, two with limited therapy upon early infection) had strong HIV specific CD4 proliferative responses and were able to maintain a CTL response even with undetectable viral load -- three patients that had delayed initiation of HAART had no HIV specific CD4 proliferative responses and lost their CTL responses when HAART was eventually given and their viral loads became undetectable.
• None of the 8 study subjects recognized this epitope but none were HLA B18+

References

Oxenius2000b A. Oxenius, D. A. Price, P. J. Easterbrook, C. A. O'Callaghan, A. D. Kelleher, J. A. Whelan, G. Sontag, A. K. Sewell, and R. E. Phillips. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U.S.A., 97(7):3382-7, 28 Mar 2000. URL: http://www.pnas.org/cgi/content/full/97/7/3382. PubMed ID: 10737796. Show all entries for this paper.